Table 1.
Question 1. Does unit have SE? | ||||||||||||
Total 84 | Yes 20 (24%) | No 64 (76%) | ||||||||||
Question 2. Proportion referred | ||||||||||||
Total 22 | <10% 2 9% | 10–19% 2 9% | 20–29% 2 9% | 30–39% 3 14% | 40–49% 1 5% | 50–59% 4 18% | 60–69% 1 5% | 70–79% 1 5% | 80–89% 2 9% | 90–99% 0 0% | 100% 3 14% | Research only 1 5% |
Question 3. Rate of non-compliance | ||||||||||||
Total 18 | < 10% 1 6% | 10–19% 4 22% | 20–29% 3 17% | 30–39% 3 17% | 40–49% 0 0% | 50–59% 6 33% | 60–69% 0 0% | 70–79% 1 6% | 80–89% 0 0% | 90–99% 0 0% | 100% 0 0% | |
Question 4. Contra-indications Angina/IHD/ACS/MI | Rest pain/tissue loss/CLI | Musculoskeletal/arthritis | Geographic/transport/distance to/Hospital | COPD/reduced PFTs/respiratory compromise | Employment constraints | Mobility problems | Hypertension | Poor compliance | Other | |||
Total 48 | 13 27% | 4 8% | 4 8% | 4 8% | 4 8% | 2 4% | 2 4% | 2 4% | 2 4% | 11 23% | ||
Question 5. Session duration | ||||||||||||
Total 20 | < 1 h 3 15% | 1 h 17 85% | 2 h 0 0% | > 2 h 0 0% | ||||||||
Question 6. Frequency of sessions | ||||||||||||
Total 20 | < 1×/week 2 10% | 1×/week 13 65% | 2×/week 4 20% | 3×/week 1 5% | > 3×/week 0 0% | |||||||
Question 7. Duration of programme | ||||||||||||
Total 20 | < 3 months 4 20% | 3 months 11 55% | 4 months 0 0% | 5 months 0 0% | 6 months 4 20% | 6–12 months 0 0% | > 1 year 0 0% | Continuous 1 5% | ||||
Question 8. Class leader | ||||||||||||
Total 29 | Physiotherapist 12 41% | Nurse 14 48% | Doctor 1 3% | Other healthcare professional 0 0% | Non-healthcare professional 2 7% | |||||||
Question 9. If no service, advice given | ||||||||||||
Total 73 | Verbal 46 63% | Leaflet 25 34% | Video 0 0% | Demonstration 2 3% | Other 0 0% | |||||||
Question 10. If no service, existing obstacles | ||||||||||||
Total 65 | Belief 1 2% | Resource 47 72% | Patient compliance 6 9% | Other 11 17% |
SE, supervised exercise; IHD, ischaemic heart disease; ACS, acute coronary syndrome; MI, myocardial infarction; CLI, critical limb ischaemia; COPD, chronic obstructive pulmonary disease; PFTs, pulmonary function tests.